Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04854096 · ClinicalTrials.gov registry record · Phase 2
Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis
A Phase 2 study, sponsored by NS Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT04854096 is a Phase 2 study that was terminated before completion, run by NS Pharma. The registered enrollment target is 7 participants.
The verdict
NCT04854096, a Phase 2 study, was terminated before completion, sponsored by NS Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study will enroll male and female subjects who are 18 years of age or older with Primary Myelofibrosis, post-polycythemia Vera Myelofibrosis, or post-essential Thrombocythemia Myelofibrosis with severe thrombocytopenia (platelet count \<50,000/µL) including subjects with intermediate-2 or high-risk MF according to the Dynamic International Prognostic Scoring System (DIPSS).
Interventions
- DRUG NS-018
- DRUG Best Available Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2023-01-31 |
| Est. Completion | 2024-05-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04854096
The ClinicalTrials.gov registry entry for NCT04854096 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NS Pharma, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which NS-018 is the first listed.
NCT04854096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04854096 about?
NCT04854096 is a clinical study titled "Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis". This study will enroll male and female subjects who are 18 years of age or older with Primary Myelofibrosis, post-polycythemia Vera Myelofibrosis, or post-essential Thrombocythemia Myelofibrosis with severe thrombocytopenia (platelet count \<50,000/µL) including subjects with intermediate-2 or high-...
What is the current status of trial NCT04854096?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2023-01-31. Estimated completion is 2024-05-16.
What interventions are being tested in trial NCT04854096?
The interventions under investigation include: NS-018 (DRUG), Best Available Therapy (DRUG).
Who is sponsoring clinical trial NCT04854096?
This trial is sponsored by NS Pharma, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.